Capital Research Global Investors Blueprint Medicines Corp Transaction History
Capital Research Global Investors
- $440 Billion
- Q1 2025
A detailed history of Capital Research Global Investors transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Capital Research Global Investors holds 311,137 shares of BPMC stock, worth $31.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
311,137Holding current value
$31.6 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
390Shares Held
68.6MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$675 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$674 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$550 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$391 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$312 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.06B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...